Increasing demand and competition for Oral Solid Dosage (OSD) products force manufacturers to optimize productivity and cost-effectiveness. Integrated Project Services (IPS) offers to facilitate.
OSD products are the dominant pharmaceuticals products form – addressing a large range of diseases and well known as well as comfortable form of medication.
The business framework for the pharmaceutical industry has changed in recent years with major influence on the manufacturing and marketing of solid dosage product. Expired patents for blockbuster products decrease the market for propriety products and increase the market for generics. The lack of new chemicals entities leads to lack of follow –up products. Cost increase in the health care sectors of the western world combined with the spread of drugs to more and more people in less developed countries make prices rise.
In The generic drug sector, manufacturers increase production capacity taking over propriety products. The traditional Big Pharma companies are leveraging their experience and know how to market quality ‘Branded Generics’.
Specialized new drugs such as sustained released formulations and combined API products as well as optimized variations of existing drugs are introduced to the market to differentiate the supplies of solid dosages forms. High potency products and new oncological products, requiring high operator protection enter the market.
Many OSD manufacturing realise the difficulty of improving their business platform on their own and therefore use consultants. Contracting with us to investigate and define the opportunities for increasing your operational excellences will inspire your organisation to move forward in the right direction.
Integrated Project Services (IPS) is deeply involved in the development of both solid dosages technologies and the increased production capacity in US, Asia.